









Markets
/
Stocks
/
nasdaq-auph
/

Aurinia Pharmaceuticals Inc

AUPH

11.060USD

-2.080-15.83%

Close 09/29, 16:00（ET）Quotes delayed by 15 min

1.47BMarket Cap

24.20P/E TTM



Aurinia Pharmaceuticals Inc

11.060

-2.080-15.83%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aurinia Pharmaceuticals Inc

Currency: USD Updated: 2025-09-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aurinia Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

76 / 505

Overall Ranking

167 / 4714

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

11.714

Target Price

-10.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aurinia Pharmaceuticals Inc Highlights

StrengthsRisks

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 75.43% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 25.26, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 77.42M shares, decreasing 1.33% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 357.00K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.56.

Financial Health

Currency: USD Updated: 2025-09-29

The company's current financial score is 9.03, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 70.01M, representing a year-over-year increase of 22.41%, while its net profit experienced a year-over-year increase of 2879.64%.

Score

Industry at a Glance

Previous score

9.03

Change



Financials

7.49

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.96

Key Metrics

Free cash flow

No Data

Aurinia Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-09-29

The company’s current valuation score is 5.10, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is 25.26, which is 784.02% below the recent high of 223.33 and 363.05% above the recent low of -66.45.

Score

Industry at a Glance

Previous score

5.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/505

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-29

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Aurinia Pharmaceuticals Inc is 11.00, with a high of 17.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

11.714

Target Price

-10.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Aurinia Pharmaceuticals Inc

AUPH

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-29

The company’s current price momentum score is 6.90, which is higher than the Biotechnology & Medical Research industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 12.95 and the support level at 9.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.03

Change

-2.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.320

Neutral

RSI(14)

35.597

Neutral

STOCH(KDJ)(9,3,3)

44.898

Sell

ATR(14)

0.631

High Vlolatility

CCI(14)

-253.852

Oversold

Williams %R

77.500

Sell

TRIX(12,20)

0.370

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

12.586

Sell

MA10

12.671

Sell

MA20

12.526

Sell

MA50

11.593

Sell

MA100

9.877

Buy

MA200

9.058

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-29

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.97. The latest institutional shareholding proportion is 58.75%, representing a quarter-over-quarter increase of 5.83%. The largest institutional shareholder is The Vanguard, holding a total of 1.69M shares, representing 1.29% of shares outstanding, with 6.45% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Tang Capital Management, LLC

10.03M

+18.98%

ILJIN SNT Co., Ltd.

8.88M

+38.78%

BlackRock Institutional Trust Company, N.A.

7.47M

-1.97%

New Enterprise Associates (NEA)

3.97M

State Street Global Advisors (US)

2.85M

-2.29%

Morgan Stanley & Co. LLC

1.74M

+76.56%

The Vanguard Group, Inc.

Star Investors

1.94M

+14.20%

Armistice Capital LLC

5.00M

-21.88%

Geode Capital Management, L.L.C.

1.73M

-1.71%

Qube Research & Technologies Ltd

856.15K

+337.35%

Risk Assessment

Currency: USD Updated: 2025-09-29

The company’s current risk assessment score is 6.35, which is higher than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 1.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.